YWYa Bin Wei

Ya Bin Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ya Bin Wei has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Photobiomodulation Ameliorates Alexander Disease Through AMPK / mTOR ‐Mediated Mitophagy

    by Nianzhuang Qiu, Jie Zhang, Huan Yi, Sihan Dong, Lei Han, Zhendong Feng, Shumin Gao, Jie Shi, Jia Jia Liu, Ye Wu, et al.

    Alexander disease (AxD) is a rare neurodegenerative disorder characterized by the pathological accumulation of Rosenthal fibers (RFs) and astrocytic inflammation. Despite advances in elucidating its genetic basis, effective therapeutic strategies remain limited. Recent studies indicate that astrocytes in AxD exhibit excessive mitochondrial fragmentation, which may cause mitochondrial dysfunction and inflammatory response. Photobiomodulation (PBM) has been shown to improve mitochondrial function and exert anti‐inflammatory effects, suggesting it may be a promising candidate for the treatment of AxD. Here, we report that exposure to 1070‐nm infrared light exerts therapeutic efficacy in AxD. Specifically, using the astrocytes derived from AxD patients and a mouse model of AxD, we demonstrate that PBM regulates AMPK/mTOR signaling and promotes mitophagy, thereby attenuating reactive oxygen species production from fragmented mitochondria and subsequent inflammatory status. This study suggests PBM may serve as a novel, non‐invasive therapeutic approach for the treatment of AxD.

  • Dissecting the shared genetic architecture and biological mechanisms linking sleep traits and suicide attempts: from variants to genes

    by Yan’E Lu, Yajing Xu, Yaoyao Sun, Yuying Li, Suhua Chang, Jianyu Que, Xikun Han, Ya Bin Wei, Catharina Lavebratt, Jia Jia Liu


  • Chronic Pain and the Risk of Dementia: A Systematic Review and Meta-Analysis

    by Qingxiu Lin, Nianzhuang Qiu, Xingxing Wang, Ya Bin Wei, Jia Jia Liu

  • Open Access

    Mll5 haploinsufficiency attenuates microglial phagocytosis through dysregulated TREM2-SGK3-GSK3β signaling and recapitulates ASD-like behaviors in mice

    by Shumin Gao, Qingxiu Lin, Xiaotong Liu, Meixiang Jia, An-Yi Zhang, Zhendong Feng, Lei Han, Nianzhuang Qiu, Xiao-Xing Liu, Huajie Zhai, et al.

    Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by persistent deficits in social communication and repetitive behaviors. Recent studies have indicated that heterozygous mutations in the mixed lineage leukemia 5 (MLL5) gene are implicated in ASD susceptibility and associated with neurodevelopmental abnormalities. However, the detailed mechanisms remain unclear. Here, we demonstrate that Mll5 haploinsufficiency in mice impairs microglial phagocytosis, drives neuronal hyperexcitability, and recapitulates core ASD-like behaviors. We also show that Mll5 acts as an epigenetic regulator, modulating microglial phagocytosis via the TREM2-SGK3-GSK3β signaling axis, which is associated with deficient glucose metabolism. Furthermore, microglia derived from individual with ASD exhibit parallel reductions in MLL5 expression and phagocytic function. By targeting this pathway, lithium chloride, a GSK3β inhibitor, rescues both microglial phagocytosis deficits and behavioral abnormalities in Mll5 haploinsufficienct mice. Our findings highlight MLL5’s critical role in ASD and its potential as a therapeutic target.


  • Alterations of the endocannabinoid system in autism spectrum disorder: a systematic review and meta-analysis

    by Xinlei Jia, Shumin Gao, Xiaotong Liu, Zhendong Feng, Xingxing Wang, Kunyi Lan, Yan’e Lu, Lei Han, Ya Bin Wei, Jia Jia Liu

    Dysregulation of the endocannabinoid system (ECS) might be related to autism spectrum disorder (ASD). This study conducts a meta-analysis on the dysregulation of the ECS across ASD animal models and individuals with ASD and systematically reviews the impact of these alterations in ASD animal models. Out of 47 papers assessed for eligibility, 16 animal studies and five human studies were included for narrative synthesis and seven and three for quantitative analysis, respectively. The results revealed a significant decrease in hippocampus anandamide (AEA) levels (SMD = −1.06, 95% CI [−1.78, −0.33], p < 0.01) among ASD animal models and a decrease in blood AEA levels in individuals with ASD (SMD = −0.79, 95% CI [−1.28, −0.30], p = 0.002) compared to normal controls. In the prefrontal cortex, 2-arachidonoylglycerol (2-AG) levels were significantly decreased, despite high heterogeneity between studies (SMD = −1.00, 95% CI [−1.93, −0.06], p = 0.04). No significant changes compared to normal controls were observed in levels of AEA (SMD = −0.48, 95% CI [−1.20, 0.25], p = 0.20), 2-AG (SMD = −0.62, 95% CI [−1.27, 0.02], p = 0.06) in combined brain regions. The narrative synthesis revealed that elevated AEA and 2-AG levels could ameliorate core and associated autistic-like symptoms with region and sex-dependent variations in ASD animal models. Future research should focus on specific mechanisms of endocannabinoids regional effects while considering sex-related influences.


  • Genetic insights into the role of mitochondria-related genes in mental disorders: An integrative multi-omics analysis

    by Yan'E Lu, Yaoyao Sun, Zhendong Feng, Xinlei Jia, Jianyu Que, Naixue Cui, Lulu Yu, Yi-Ran Zheng, Ya Bin Wei, Jia Jia Liu


  • The association between couple relationships and sleep: A systematic review and meta-analysis

    by Xing Xing Wang, Qingxiu Lin, Xiaotong Liu, Ping Dong, Yanping Bao, Jian-Yu Que, Lin Lu, Ya Bin Wei, Jia Jia Liu


  • Association between blood mitochondrial DNA copy number and mental disorders: A bidirectional two-sample mendelian randomization study

    by Yan’e Lu, Lei Han, Xingxing Wang, Xiaotong Liu, Xinlei Jia, Kunyi Lan, Shumin Gao, Zhendong Feng, Lulu Yu, Qian Yang, et al.


  • Mental health conditions in patients with systemic lupus erythematosus: a systematic review and meta-analysis

    by Xiaotong Liu, Xinlei Jia, Xiao Wang, Ya Bin Wei, Jia Jia Liu

    The reported prevalence of mental health conditions (MHCs) in people with systemic lupus erythematosus (SLE) ranges widely. Whether MHCs are associated with increased risk of SLE or the outcomes of the disease is unclear. This study aimed to conduct an umbrella and updated meta-analysis of MHCs in people with SLE and to identify whether MHCs are associated with the risk of SLE or patient outcomes. We comprehensively searched PubMed, Web of Science and Embase databases to identify relevant studies published before June 2023. Random-effect models were used to calculate the pooled prevalence and risk ratios (RR) for each MHC. In total, 203 studies with 1 485 094 individuals were included. The most MHCs observed in patients with SLE were sleep disturbance (59.7% [95% CI, 52.4–66.8%]) among adults and cognitive dysfunction (63.4% [95% CI, 46.9–77.9%]) among children. We found that depressive disorders (RR = 2.30, 95% CI = 1.94–2.75) and posttraumatic stress disorder (RR = 1.93, 95% CI = 1.61–2.31) in the general population were significantly associated with an increased likelihood of developing SLE. Furthermore, concurrent MHCs were linked to unfavourable outcomes in patients with SLE, such as decreased quality of life, increased risk of unemployment and other somatic comorbidities. Our study demonstrated a high prevalence of MHCs among patients with SLE. Individuals with pre-existing mental disorders exhibited an elevated susceptibility to developing SLE and patients presenting with MHCs were at increased risk of experiencing suboptimal health and functional outcomes. Therefore, evaluating and preventing MHCs should be considered as an integral component of the comprehensive treatment strategy for SLE.


  • Open Access

    Virtual reality‐based cognitive–behavioural therapy for the treatment of anxiety in patients with acute myocardial infarction: a randomised clinical trial

    by Yuanyuan Li, Juan Peng, Pingyuan Yang, Jiajun Weng, Yan'E Lu, Jiajia Liu, Shikun Xu, Lihua Guan, Dong Huang, Qibing Wang, et al.

    Background The presence of mental health conditions is pervasive in patients who experienced acute myocardial infarction (AMI), significantly disrupting their recovery. Providing timely and easily accessible psychological interventions using virtual reality-based cognitive–behavioural therapy (VR-CBT) could potentially improve both acute and long-term symptoms affecting their mental health. Aims We aim to examine the effectiveness of VR-CBT on anxiety symptoms in patients with AMI who were admitted to the intensive care unit (ICU) during the acute stage of their illness. Methods In this single-blind randomised clinical trial, participants with anxiety symptoms who were admitted to the ICU due to AMI were continuously recruited from December 2022 to February 2023. Patients who were Han Chinese aged 18–75 years were randomly assigned (1:1) via block randomisation to either the VR-CBT group to receive VR-CBT in addition to standard mental health support, or the control group to receive standard mental health support only. VR-CBT consisted of four modules and was delivered at the bedside over a 1-week period. Assessments were done at baseline, immediately after treatment and at 3-month follow-up. The intention-to-treat analysis began in June 2023. The primary outcome measure was the changes in anxiety symptoms as assessed by the Hamilton Anxiety Rating Scale (HAM-A). Results Among 148 randomised participants, 70 were assigned to the VR-CBT group and 78 to the control group. The 1-week VR-CBT intervention plus standard mental health support significantly reduced the anxiety symptoms compared with standard mental health support alone in terms of HAM-A scores at both post intervention (Cohen’s d=−1.27 (95% confidence interval (CI): −1.64 to −0.90, pConclusions Our results indicate that VR-CBT can significantly reduce post-AMI anxiety at the acute stage of the illness; the improvement was maintained at the 3-month follow-up. Trial registration number The trial was registered at www.chictr.org.cn with the identifier: ChiCTR2200066435.